

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	July 9, 2019 May 19, 2022, January 27, 2023, March 18, 2025, April 4, 2025

ABILIFY MYCITE® (aripiprazole tablets with sensor)

LENGTH OF AUTHORIZATION: THREE MONTHS

Abilify MyCite is a drug-device combination product comprised of aripiprazole and a sensor embedded in the tablets, intended to track drug ingestion. Most ingestions of Abilify MyCite will be detected within 30 minutes, but may take up to two hours to detect on the smartphone app. Its use is not for real time ingestion or emergency monitoring. Abilify MyCite has not been shown to improve patient adherence.

THIS MEDICATION MAY RECEIVE APPROVAL UNDER TWO CRITERIA

REVIEW CRITERIA:

- Patient must be ≥18 years old.
- Diagnosis of schizophrenia, bipolar I disorder, or major depressive disorder is documented.
- Patient must have a history, within the past 365 days of trial and failure of a preferred atypical antipsychotic with a minimum 30-day treatment period.
- Documentation of non-compliance not related to intolerance or allergic reaction to an atypical antipsychotic.

ALTERNATE REVIEW CRITERIA

- Clinical documentation of medical necessity because:
 - The patient has a diagnosis of schizophrenia, schizotypal or delusional disorder and meets the following:
 - The drug product or medication of a similar drug class is prescribed for the treatment of schizophrenia or schizotypal or delusional disorders; **-AND-**
 - Prior authorization has been granted previously for the prescribed drug; **-AND-**
 - The medication was dispensed to the patient during the previous 12 months

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg tablets with sensor.